Earnings Call Summary | PetMed Express(PETS.US) Q4 2024 Earnings Conference
Earnings Call Summary | PetMed Express(PETS.US) Q4 2024 Earnings Conference
The following is a summary of the PetMed Express, Inc. (PETS) Q4 2024 Earnings Call Transcript:
以下是PetMed Express, Inc.（PETS）2024年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
For Q4 2024, PetMed Express reported a revenue of $66.5 million, reflecting a 6.6% increase year-over-year, primarily driven by the acquisition of PetCareRx.
Gross profit margin for the fourth quarter was listed at 27.3%, experiencing a slight decrease from 27.9% in the same quarter last year.
The company reported a net loss of $5 million or $0.25 per diluted share, compared to a net loss of $200,000 or $0.01 per diluted share in the prior year's same quarter.
2024年第四季度，PetMed Express公佈的收入爲6,650萬美元，同比增長6.6％，這主要是由對PetCareRx的收購推動的。
第四季度的毛利率爲27.3％，較去年同期的27.9％略有下降。
該公司報告淨虧損500萬美元，攤薄每股虧損0.25美元，而去年同期淨虧損20萬美元，攤薄每股虧損0.01美元。
Business Progress:
業務進展：
PetMed Express is focusing on integrating its PetMeds and PetCareRx brands to create a more streamlined operation.
The company is enhancing key relationships with suppliers, improving inventory management, and taking steps to reduce operational costs through consolidation and enhanced technology use.
The company appointed new members to key roles including Chief Marketing Officer and Chief Digital and Technology Officer to drive forward technological improvements and marketing strategies.
PetMed Express專注於整合其PetMeds和PetCareRx品牌，以創建更加簡化的運營。
該公司正在加強與供應商的關鍵關係，改善庫存管理，並採取措施通過整合和加強技術使用來降低運營成本。
該公司任命了新成員擔任關鍵職務，包括首席營銷官和首席數字和技術官，以推動技術改進和營銷戰略。
Opportunities:
機會：
The continued growth in the pet care sector, particularly in medication, food, and health services, presents significant opportunities for PetMed Express.
PetMed Express is expanding its digital capabilities and automation to enhance efficiencies and customer interactions.
寵物護理行業的持續增長，尤其是藥物、食品和健康服務領域的持續增長，爲PetMed Express帶來了巨大的機遇。
PetMed Express正在擴展其數字能力和自動化以提高效率和客戶互動。
Risks:
風險：
There was no explicit mention of specific risks facing the company in the forward-looking statements.
前瞻性陳述中沒有明確提及公司面臨的具體風險。
More details: PetMed Express IR
更多詳情： PetMed Express 投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。